Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × aflibercept × CNS × Clear all

Phase

Phase 3 1 Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 5 Thoracic 1 Genitourinary 1 Dermatologic 1 CNS 1

Conditions

Neurofibromatosis 2 1 Macular Degeneration 1

Interventions

Radiotherapy 61 Temozolomide 55 Vincristine 32 Cyclophosphamide 31 Carboplatin 29 Radiosurgery 24 Etoposide 24 Cisplatin 24 Lomustine 23 Filgrastim 17 Magnetic Resonance Spectroscopy 15 Doxorubicin 14 Bevacizumab 13 Radiation 12 Granulocyte Colony-Stimulating Factor 12 Isotretinoin 10 Carmustine 10 Surgical Procedures, Operative 9 Procarbazine 9 Peripheral Blood Stem Cell Transplantation 9 Melphalan 9 Chemotherapy, Adjuvant 9 Specimen Handling 8 Platinum 8 etoposide phosphate 7 sargramostim 6 Topotecan 6 Radiotherapy, Intensity-Modulated 6 Neoadjuvant Therapy 6 Ifosfamide 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03710564 2023-01-30

MERLIN

Novartis

Phase 3 Terminated

535 enrolled 14 charts

Macular Degeneration, Neurofibromatosis 2

Data powered by HemOnc (CC BY 4.0) Colophon ⚡